Wellington Management Group LLP Has $1.10 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

Wellington Management Group LLP decreased its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 4.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 143,207 shares of the company’s stock after selling 6,570 shares during the quarter. Wellington Management Group LLP’s holdings in Tango Therapeutics were worth $1,103,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in Tango Therapeutics in the second quarter worth $3,836,000. Quarry LP bought a new position in shares of Tango Therapeutics during the 2nd quarter worth about $99,000. Point72 DIFC Ltd acquired a new stake in shares of Tango Therapeutics in the 2nd quarter valued at about $54,000. Dimensional Fund Advisors LP increased its position in Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new position in Tango Therapeutics during the 3rd quarter worth approximately $247,000. Institutional investors own 78.99% of the company’s stock.

Insider Transactions at Tango Therapeutics

In related news, Director Mace Rothenberg purchased 10,000 shares of Tango Therapeutics stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average price of $3.78 per share, for a total transaction of $37,800.00. Following the completion of the transaction, the director now owns 31,250 shares in the company, valued at $118,125. This represents a 47.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Boxer Capital Management, Llc sold 3,080,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $3.14, for a total transaction of $9,671,200.00. Following the sale, the insider now owns 3,610,642 shares of the company’s stock, valued at $11,337,415.88. This trade represents a 46.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,338,000 shares of company stock worth $18,426,160 in the last 90 days. Insiders own 6.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on TNGX. Guggenheim reduced their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. Finally, B. Riley decreased their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $13.14.

Tango Therapeutics Stock Performance

Tango Therapeutics stock opened at $2.94 on Friday. Tango Therapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $13.01. The firm’s 50-day simple moving average is $4.48 and its 200 day simple moving average is $7.49. The stock has a market cap of $315.81 million, a PE ratio of -2.49 and a beta of 0.74.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.